SOMERSET, N.J., July 30, 2008 (PRIME NEWSWIRE) -- inVentiv Health, Inc. (Nasdaq:VTIV), a leading provider of commercialization services to the global pharmaceutical and healthcare industries, today announced two management appointments. Dan Rubin has been named President of inVentiv Patient Outcomes and Norman Stalsberg has been named President of inVentiv Strategy & Analytics.
In his new role, Mr. Rubin will lead the Patient Outcomes division, which works with pharmaceutical manufacturers, healthcare providers, pharmacists and payers to develop programs that help patients achieve the best possible medical outcomes. Companies within the division include Adheris, AWAC, The Franklin Group and The Therapeutics Institute.
Prior to this role, Mr. Rubin served as CEO and co-founder of Adheris, a patient compliance company that inVentiv acquired in 2006. In his 15 years overseeing the company, he led it to become the largest provider of retail-based patient adherence programs for the pharmaceutical industry. Before founding Adheris, Mr. Rubin led several consulting engagements in the pharmaceutical, retail, high technology and chemical industries at Corporate Decisions, Inc., a management consulting firm. He also has held management positions with Dynisco LLC, Unocal and Motorola.
Mr. Stalsberg will oversee inVentiv Strategy & Analytics, the division of inVentiv Commercial that provides consulting, commercialization planning, research and data analytics to healthcare clients. The companies within Strategy & Analytics include CHS, Health Products Research (HPR), Strategyx and Ventiv Access Services.
Prior to this position, Mr. Stalsberg served as President of CHS, an inVentiv company that provides outsourced marketing solutions to pharmaceutical and biotech companies. Mr. Stalsberg has more than 20 years of experience in the consumer packaged goods, pharmaceutical and information services industries. Before joining CHS, he served as Vice President/General Manager, Consumer Products Group for NDC Health Information Services and as Marketing Director in their Pharmaceutical Information Services division.
"Dan and Norman both have outstanding leadership experience and vision, having grown small ventures into thriving businesses. I believe the skills and perspective they bring to these new roles will be a tremendous asset to our organization," said Blane Walter, Chief Executive Officer of inVentiv Health.
Mr. Rubin and Mr. Stalsberg will report to Terry Herring, CEO of inVentiv Commercial and inVentiv Patient Outcomes, and COO of inVentiv Health. Both Mr. Rubin and Mr. Stalsberg will serve on the inVentiv Health Leadership Team.
About inVentiv Health
inVentiv Health, Inc. (Nasdaq:VTIV) is an insights-driven global healthcare leader that provides dynamic solutions to deliver customer and patient success. inVentiv delivers its customized clinical, sales, marketing and communications solutions through its four core business segments: inVentiv Clinical, inVentiv Communications, inVentiv Commercial, and inVentiv Patient Outcomes. inVentiv Health's client roster is comprised of more than 350 leading pharmaceutical, biotech, life sciences and healthcare payor companies, including all top 20 global pharmaceutical manufacturers. For more information, visit www.inventivhealth.com.
The inVentiv Health, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4942
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by inVentiv Health, Inc. with the Securities and Exchange Commission for further discussion of these and other factors.